All In Biotech

Drug Trial Radar · NCT05415410

Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)

A Randomized, Single-blind Trial to Evaluate the Safety and Efficacy of Apraglutide in Subjects With Grade II to IV (MAGIC) Steroid Refractory Gastrointestinal (GI) Acute Graft Versus Host Disease on Best Available Therapy

Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

31

Actual

Start

May 25, 2022

Primary completion

Dec 17, 2024

Study completion Dec 17, 2024

Sponsor

Lead sponsor
VectivBio AGIndustry
Sponsor type
Industry
First posted
Jun 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this trial is to assess safety and efficacy of apraglutide in subjects with steroid refractory gastrointestinal aGVHD.

Conditions

  • GVHD

Interventions

  • ApraglutideDrug

    Apraglutide is a new, synthetic glucagon-like peptide 2 (GLP-2) receptor agonist which acts as a gut targeted regenerative approach that is intestinotrophic with a mode of action that improves absorption and enhances gut barrier function.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Screening (up to 12 weeks) through End of Trial (up to 2 years/104 weeks) for a total of up to 116 weeks
  2. Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESIs)Time frame: From first dose of study drug through End of Trial (up to 2 years/104 weeks) for a total of up to 116 weeks
  3. Number of Participants With Clinically Significant Changes From Baseline Over Time in Vital SignsTime frame: Baseline, Weeks 1, 2, 3, 4, 6, 8, 13, 17, 21, 26, 52, End of Treatment (up to Week 25), Week 104/End of Trial
  4. Number of Participants With Clinically Significant Changes From Baseline Over Time in QT Corrected for Heart Rate Using Fridericia's Formula (QTcF)Time frame: Baseline, Weeks 26, 52, 104/End of Trial
  5. Number of Participants With Potentially Clinically Significant Values Over Time in Liver Function Tests: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)Time frame: Baseline, Weeks 1, 2, 3, 4, 6, 8, 13, 17, 21, 26, 52, End of Treatment (up to Week 25), Week 104/End of Trial
  6. Number of Participants With Potentially Clinically Significant Values Over Time in Liver Function Tests: Total BilirubinTime frame: Baseline, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 52, End of Treatment (up to Week 25), Week 104/End of Trial
  7. Number of Participants With Potentially Clinically Significant Values Over Time in Liver Function Tests: Potential Hy's Law CasesTime frame: Baseline, Weeks 1, 2, 3, 4, 6, 8, 13, 17, 21, 26, 52, End of Treatment (up to Week 25), Week 104/End of Trial
  8. Number of Participants With Anti-drug Antibodies (ADAs) Over TimeTime frame: Baseline, Weeks 1, 2, 3, 4, 6, 8, 13, 17, 21, 26, 52, End of Treatment (up to Week 25), Week 104/End of Trial
  9. Shift Table From Baseline to Worst Post-Treatment (WPT) Physical ExaminationsTime frame: Baseline (BL), up to Week 104/End of Treatment

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Center

    Stanford, California

  • University of Iowa

    Iowa City, Iowa

  • Massachusetts General Hospital

    Boston, Massachusetts

  • The Ohio State University

    Columbus, Ohio

  • South Austin Medical Center

    Austin, Texas

  • Universitätsklinikum Köln (AoeR)

    Cologne, Germany

  • Universitaetsklinikum Duesseldorf

    Düsseldorf, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Martin Luther Universität Halle-Wittenberg

    Halle, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Universitätsmedizin der Johannes Gutenberg - Universität Mainz

    Mainz, Germany

  • Instituto Portugues de Oncologia do Porto Francisco Gentil

    Porto, Portugal

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.